Frequencies of both CD8+ IFN-γ+ and CD4+ IFN-γ+ tumor-infiltrating lymphocytes (TILs) were also reduced within the gefitinib-treated group (Fig. 2f and Supplementary Fig. 2g, h). This evidence concerns the gene CD4 and neoplasm.